We are live on
!
Find out more
VPC
Vestal Point Capital Portfolio holdings
AUM
$3.58B
1-Year Est. Return
190.75%
This Fund
S&P 500
1 Year Est. Return
+190.75%
AUM
$3.58B
AUM Growth
+$851M
(+31%)
Holding
113
Top Buys
| 1 | +$210M | |
| 2 | +$166M | |
| 3 | +$118M | |
| 4 |
Arrowhead Research
ARWR
|
+$87M |
| 5 |
Immunocore
IMCR
|
+$70.6M |
Top Sells
| 1 | +$191M | |
| 2 | +$144M | |
| 3 | +$84.6M | |
| 4 |
Merck
MRK
|
+$81.6M |
| 5 |
Tyra Biosciences
TYRA
|
+$76.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Revolution Medicines
RVMD
$32.7B
| $231M | 6.46% |
2,375,000
+2,080,000
|
|
||
2
BioMarin Pharmaceuticals
BMRN
$10.8B
| $202M | 5.65% |
3,575,000
+575,000
|
|
||
|
ABVX
3
Abivax
ABVX
$7.7B
| $167M | 4.67% |
1,500,000
-400,000
|
|
||
4
Neurocrine Biosciences
NBIX
$16.1B
| $165M | 4.6% |
+1,250,000
|
|
||
|
5
Arrowhead Research
ARWR
$10.5B
| $143M | 3.99% |
2,275,000
+1,375,000
|
|
||
6
Enliven Therapeutics
ELVN
$2.81B
| $127M | 3.56% |
3,250,000
-580,000
|
|
||
7
Repligen
RGEN
$7.37B
| $109M | 3.05% |
925,000
+842,000
|
|
||
|
BCAX
8
Bicara Therapeutics
BCAX
$1.43B
| $108M | 3.02% |
5,425,000
+1,850,000
|
|
||
9
Nurix Therapeutics
NRIX
$1.75B
| $101M | 2.82% |
6,500,000
+1,810,000
|
|
||
10
Apogee Therapeutics
APGE
$6.66B
| $92.6M | 2.59% |
1,100,000
+550,000
|
|
||
11
Ascendis Pharma A/S
ASND
$14.3B
| $85.8M | 2.4% |
375,000
+200,000
|
|
||
|
12
Immunocore
IMCR
$1.47B
| $83.4M | 2.33% |
2,766,868
+2,181,868
|
|
||
13
Taysha Gene Therapies
TSHA
$1.64B
| $80.5M | 2.25% |
18,000,000
+4,250,000
|
|
||
14
Dyne Therapeutics
DYN
$3.01B
| $72.5M | 2.03% |
4,000,000
+3,880,000
|
|
||
15
Sanofi
SNY
$106B
| $67.5M | 1.89% |
+1,400,000
|
|
||
16
BioCryst Pharmaceuticals
BCRX
$2.21B
| $66.9M | 1.87% |
7,025,000
+4,775,000
|
|
||
17
Scholar Rock
SRRK
$5.29B
| $65.1M | 1.82% |
1,324,422
+624,422
|
|
||
18
Immatics
IMTX
$1.28B
| $60.8M | 1.7% |
6,175,000
+50,000
|
|
||
19
Bristol-Myers Squibb
BMY
$117B
| $60.6M | 1.7% |
1,000,000
+750,000
|
|
||
20
Alcon
ALC
$32.6B
| $60.3M | 1.69% |
800,000
-305,000
|
|
||
21
Monte Rosa Therapeutics
GLUE
$1.54B
| $59.3M | 1.66% |
3,603,465
+2,828,465
|
|
||
22
Vera Therapeutics
VERA
$2.46B
| $55M | 1.54% |
1,368,159
+818,159
|
|
||
|
TERN
23
DELISTED
Terns Pharmaceuticals
TERN
| $52.7M | 1.47% |
1,000,000
-3,500,000
|
|
||
24
Globus Medical
GMED
$10.9B
| $52.6M | 1.47% |
610,520
-664,480
|
|
||
25
Boston Scientific
BSX
$69.7B
| $50.2M | 1.4% |
+800,000
|
|